<SEC-DOCUMENT>0000903423-18-000545.txt : 20181010
<SEC-HEADER>0000903423-18-000545.hdr.sgml : 20181010
<ACCEPTANCE-DATETIME>20181010195146
ACCESSION NUMBER:		0000903423-18-000545
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20181010
FILED AS OF DATE:		20181010
DATE AS OF CHANGE:		20181010

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Sisitsky Todd Benjamin
		CENTRAL INDEX KEY:			0001407884

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		181117119

	MAIL ADDRESS:	
		STREET 1:		TPG CAPITAL
		STREET 2:		345 CALIFORNIA STREET, SUITE 3800
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>sisitisky.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2018-10-10</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001737287</issuerCik>
        <issuerName>Allogene Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>ALLO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001407884</rptOwnerCik>
            <rptOwnerName>Sisitsky Todd Benjamin</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O TPG GLOBAL, LLC</rptOwnerStreet1>
            <rptOwnerStreet2>301 COMMERCE STREET, SUITE 3300</rptOwnerStreet2>
            <rptOwnerCity>FORT WORTH</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>76102</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>No securities beneficially owned</value>
                <footnoteId id="F1"/>
                <footnoteId id="F2"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Todd Benjamin Sisitsky is a TPG Partner. TPG is affiliated with each of (i) TPG Carthage Holdings, L.P., which directly holds 2,852,071 shares of Series A Preferred Stock (&quot;Series A Preferred&quot;) of Allogene Therapeutics, Inc. (the &quot;Issuer&quot;), and (ii) The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the &quot;TPG Funds&quot;), which directly holds 1,426,036 shares of Series A Preferred.</footnote>
        <footnote id="F2">Mr. Sisitsky disclaims beneficial ownership of all of the securities that are or may be beneficially owned by the TPG Funds or any of their affiliates. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;), this filing shall not be deemed an admission that Mr. Sisitsky is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer for purposes of Section 16 of the Exchange Act or otherwise.</footnote>
    </footnotes>

    <remarks>(3) Michael LaGatta is signing on behalf of Mr. Sisitsky pursuant to the authorization and designation letter dated October 3, 2016, which was previously filed with the Securities and Exchange Commission.</remarks>

    <ownerSignature>
        <signatureName>/s/ Michael LaGatta on behalf of Todd Benjamin Sisitsky (3)</signatureName>
        <signatureDate>2018-10-10</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
